StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

Equities research analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

NASDAQ EVOK opened at $3.96 on Tuesday. The company’s 50 day moving average is $4.65 and its 200-day moving average is $4.76. Evoke Pharma has a 12-month low of $3.44 and a 12-month high of $12.32. The firm has a market cap of $5.88 million, a P/E ratio of -0.36 and a beta of 0.16.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.